Europe is expected to transform its clinical research ecosystem to regain global competitiveness. An increasing share of multinational clinical trials has shifted to the United States and Asia, attracted by faster approvals and streamlined regulations.
To reverse this trend, the European regulatory network has launched a coordinated strategy to make the EU a more appealing location for clinical research. Key to this effort is the Clinical Trials Coordination Group (CTCG), a working group within the Heads of Medicines Agencies (HMA) that brings together experts from national regulatory authorities responsible for clinical trial assessment and oversight.
The CTCG aims to strengthen the European regulatory environment for clinical trials while guaranteeing patient safety, data quality, and scientific robustness. According to the CTCG Workplan 2026–2027, the group works to harmonize regulations and optimize procedures within Member States, ultimately enabling patients to access innovative therapies faster.
The power of digital infrastructure
The ACT EU initiative functions as a key pillar of this progress, promoting smarter clinical trials through regulatory innovation, improved processes, and advanced digital technologies. However, achieving these goals requires more than regulatory reform.
To support multinational clinical trials, Europe must also adopt a solid digital infrastructure. This infrastructure should be capable of directing complex, cross-border research operations.
Discover how ACTide supports multinational clinical trials in Europe.
Breaking the 200-day barrier: speed through automation
A key goal of Europe’s strategy is to reduce the time needed to launch clinical trials. The ACT EU program has introduced a clear target: Two-thirds of clinical trials should begin recruiting patients within 200 days of submission, compared with only about half of trials reaching this benchmark today. To reach this objective, the European regulatory network is implementing new initiatives created to streamline trial approval procedures and accelerate study startup.
Among the most relevant initiatives is FAST-EU, a pilot program exploring shortened timelines for clinical trial assessment through Member States. (FAST-EU: “Facilitated Assessment of Studies and Trials in the European Union” pilot) regulatory upgrades alone do not eliminate all delays.
Digital solutions for operational efficiency
Many operational bottlenecks arise during study setup, when sponsors coordinate documents, regulatory submissions, and study configurations through multiple countries. Digital solutions eliminate those inefficiencies by enabling:
- rapid study build-out.
- Standardized trial templates.
- Automated workflow management.
- Centralized document governance.
Platforms such as ACTide enable sponsors and CROs to quickly configure multinational studies while continuing regulatory compliance and consistent data governance.
Accelerate the clinical trial startup with ACTide’s digital ecosystem.
Supporting innovative methodologies: decentralized trials and adaptive designs
Another strategic priority for European regulators is the implementation of innovative c clinical trial methodologies. The CTCG workplan emphasizes advancing new research approaches, including decentralized clinical trials and innovative study designs. Decentralized Clinical Trials (DCTs) allow participants to interact with research teams remotely, reducing logistical barriers and increasing patient e engagement.
These models rely on digital infrastructures capable of supporting secure remote data capture and centralized monitoring. Key digital capabilities required for decentralized and multinational trials include:
- secure remote access to study platforms.
- Real-time data transfer b between sites.
- Centralized monitoring dashboards.
- Electronic consent and digital signatures.
Digital tools, such as eConsent systems, enable sponsors to manage consent documentation efficiently while ensuring compliance with national regulations across EU Member States.
Empower your next decentralized clinical trial, see how ACTide delivers compliance and flexibility for trials across Europe.
Get your free demo here:
AI and advanced data analytics in clinical research
Artificial intelligence is increasingly acknowledged as a key driver of innovation in clinical trial management.
The CTCG workplan identifies AI use cases for clinical trial assessment and regulatory review as one of the innovation projects under development for 2026–2027.
AI technologies can help optimize many aspects of clinical trials, including:
- predictive patient enrollment modelling.
- Automated anomaly detection datasets.
- Site performance monitoring.
- Risk-based trial oversight.
However, these capabilities depend on high-quality structured data collected over digital platforms. Modern eClinical infrastructures must therefore capture standardized data, govern data centrally, ensure interoperability between systems, and maintain audit-ready documentation.
ACTide’s integrated eClinical environment satisfies these requirements by providing a robust, structured d data ecosystem for advanced analytics and AI-driven trial management.
Discover how ACTide supports AI-ready clinical data management.
Harmonization through technology: reducing fragmentation
One of the persistent challenges for multinational clinical trials in Europe has been regulatory fragmentation between Member States. Even under the new Clinical Trials Regulation, operational differences between national authorities can still complicate trial execution.
The CTCG strategy therefore emphasizes collaboration among regulatory agencies, ethics committees, and all the stakeholders to improve consistency and predictability across Europe. Digital platforms play a key role in enabling this harmonization.
By serving as a Single Source of Truth, integrated clinical trial systems ensure that all stakeholders have access to the same validated information. Essential capabilities for multinational trial governance include:
- centralized trial data repositories.
- Unified monitoring dashboards.
- Standardized workflows across countries.
- Robust audit trails for regulatory inspections.
These infrastructures ensure compliance with the governance standards promoted by the ACT EU initiative.
Choosing the right partner for the new EU era
Europe’s clinical trial ecosystem is undergoing a major transformation.
Through initiatives such as ACT EU, the CTCG workplan, and the FAST-EU pilot program, regulators aim to make Europe faster, more coordinated, and more attractive for multinational clinical trials. The strategic vision for 2027 is clear:
- faster regulatory processes.
- Increased multinational collaboration.
- Stronger patient involvement.
- Greater use of digital technologies and AI.
However, achieving these goals will require sponsors and CROs to adopt advanced digital infrastructures to support complex multinational studies.
Integrated eClinical ecosystems like ACTide provide the technological foundation for effectively managing clinical data, ensuring regulatory compliance, and supporting the next generation of digital clinical trials in Europe.
Find out how ACTide assist your next European clinical trial: